



## Zynerba Pharmaceuticals Announces Poster Presentation at the 2018 Annual Meeting of the American Academy of Neurology (AAN)

March 22, 2018

DEVON, Pa., March 22, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare neurological and psychiatric disorders with high unmet medical needs, today announced the acceptance and presentation details of a late breaking poster at the 2018 Annual Meeting of the American Academy of Neurology (AAN) in Los Angeles, CA from April 21<sup>st</sup> through 27<sup>th</sup>, 2018. The poster has been accepted to the Emerging Science session at the AAN.

### Wednesday April 25, 2018

**Poster title: "Transdermal Cannabidiol (CBD) Gel for the Treatment of Focal Epilepsy in Adults"**

*Session: Emerging Science - poster presentations*

*Poster session: IV*

*Poster number: P4.468*

*Author presentation time: 5:30PM – 7:30PM EDT*

*Display time: 11:30AM – 7:00PM EDT*

### About Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) is a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric diseases with high unmet medical needs. We are dedicated to improving the lives of people with severe health conditions by developing cannabinoid medicines designed to meet the rigorous efficacy and safety standards established by global regulatory agencies. Through the discovery and development of these potentially life-changing medicines, Zynerba seeks to improve the lives of patients battling severe, chronic health conditions including Fragile X syndrome, refractory epilepsies, Tourette Syndrome, and other neuropsychiatric disorders. Learn more at [www.zynerba.com](http://www.zynerba.com) and follow the Company on Twitter at @ZynerbaPharma.

### Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company's current expectations. These and other risks are described in the Company's periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at [www.sec.gov](http://www.sec.gov). Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

### Zynerba Contact

Will Roberts, VP Investor Relations and Corporate Communications

484.581.7489

[robertsw@zynerba.com](mailto:robertsw@zynerba.com)

### Media contact

Theresa Dolge

Tonic Life Communications

Office: 215-928-2748

[Theresa.Dolge@toniclc.com](mailto:Theresa.Dolge@toniclc.com)

[Primary Logo](#)

Zynerba Pharmaceuticals, Inc.